First Republic Investment Management, Inc. Immuno Gen, Inc. Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $27,373 - $70,562	-12,166 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$2.22 - $3.39 $7,212 - $11,014	-3,249 Reduced 21.08%	12,166 $29,000
Q2 2019 Aug 07, 2019	SELL	$1.8 - $3.3 $4,690 - $8,599	-2,606 Reduced 14.46%	15,415 $33,000
Q1 2019 Apr 30, 2019	SELL	$2.41 - $5.91 $3,267 - $8,013	-1,356 Reduced 7.0%	18,021 $49,000
Q4 2018 Feb 12, 2019	SELL	$3.94 - $9.7 $7,990 - $19,671	-2,028 Reduced 9.47%	19,377 $93,000
Q3 2018 Nov 13, 2018	SELL	$8.6 - $11.26 $4,394 - $5,753	-511 Reduced 2.33%	21,405 $203,000
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $20,001 - $25,527	2,101 Added 10.6%	21,916 $213,000
Q1 2018 May 10, 2018	BUY	$6.7 - $12.95 $10,579 - $20,448	1,579 Added 8.66%	19,815 $209,000
Q4 2017 Feb 09, 2018	SELL	$5.07 - $7.92 $98,439 - $153,774	-19,416 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $104,846 - $164,453	19,416	19,416 $149,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account